SuperworthXilio Therapeutics EPS XLO
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- n/m
- a quarter missing
- Latest quarter, Q2 FY26
- −$0.33
- Fiscal year 2024
- −$17.92
Xilio Therapeutics' twelve-month earnings per share can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q2 FY26, it was −$0.33.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2024 | −$17.92 | n/a |
| FY2023 | −$38.92 | n/a |
| FY2022 | −$45.08 | n/a |
| FY2020 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.33 | n/a | n/a | |
| Q1 FY26 | −$0.58 | n/a | n/a | |
| Q3 FY25 | −$1.54 | n/a | −$9.13 | |
| Q2 FY25 | −$2.30 | n/a | −$10.67 | |
| Q1 FY25 | −$2.49 | n/a | −$11.73 | |
| Q4 FY24 | −$2.80 | n/a | −$17.92 | |
| Q3 FY24 | −$3.08 | n/a | −$24.08 | |
| Q2 FY24 | −$3.36 | n/a | −$29.54 | |
| Q1 FY24 | −$8.68 | n/a | −$35.98 | |
| Q4 FY23 | −$8.96 | n/a | −$38.92 | |
| Q3 FY23 | −$8.54 | n/a | −$41.44 | |
| Q2 FY23 | −$9.80 | n/a | −$42.98 |
Against its peers
Companies in Drug Manufacturers - General nearest Xilio Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| XLOXilio Therapeutics | n/m | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| Peer median | $0.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Xilio Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.